Denileukin diftitox effective in relapsed/refractory B-cell NHL

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1460, 2004-01, pp. : 16-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Radioimmunotherapy of B-Cell NHL

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 327-339

Bentham Science Publishers

Access to resources Recommend Favorite

Low-dose denileukin diftitox regimen effective in severe psoriasis

Inpharma, Vol. 1, Iss. 1321, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Denileukin diftitox improves QOL in cutaneous T-cell lymphoma

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 360, 2002-01 ,pp. : 10-11

Adis International

Access to resources Recommend Favorite

Denileukin diftitox has promising activity in graft-versus-host disease (GVHD) following haematopoietic stem cell transplantation

Inpharma, Vol. 1, Iss. 1458, 2004-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

Blackwell Publishing

Access to resources Recommend Favorite